Despite the ongoing debate, study finding support retaining the “cancer” designation for patients with Gleason grade group 1 ...

Survival after moderate HFRT in patients with high-risk prostate cancer was a secondary outcome of the randomized phase 3 Prostate Cancer Study 5 trial.

I am a 73-year-old who underwent successful treatment for prostate cancer, using hormone suppression and radiation in 2015. After the treatment concluded, my testosterone level increased back to 435 ...

The survival rate of men with prostate cancer who had their entire prostate gland removed immediately after the tumor was ...

The following is a summary of “Characteristics of lymphoedema, in particular midline lymphoedema, after treatment for ...

It may be time to rebrand low-grade prostate cancer to something other than “cancer,” a group of international experts says. Prostate cancer is one of the most common forms of the disease ...

Late biochemical recurrence was seen in 5% of patients with prostate cancer who had uneventful follow ... to metastasis were “strikingly low” in patients with pT2 stage disease and ...

In 2022, there were nearly 1.5 million cases of prostate cancer, but only 400,000 deaths. Low-grade prostate cancer, commonly known as GG1 among physicians, virtually never metastasizes or causes ...

It may be time to rebrand low-grade prostate cancer to something other than “cancer,” a group of international experts says. Prostate cancer is one of the most common forms of the disease globally, ...

These conclusions stem, in part, from advances that have allowed prostate cancer diagnoses of very low-grade disease. In other words, typically indolent prostate cancer cases, categorized as Grade ...

In 2022, there were nearly 1.5 million cases of prostate cancer, but only 400,000 deaths. Low-grade prostate cancer, commonly known as GG1 among physicians, virtually never metastasizes or causes ...